02.08.2016
Eckert & Ziegler Strahlen- und Medizintechnik AG DE0005659700
DGAP-News: Eckert & Ziegler: Significant improvement in cost items in the first half year
DGAP-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s):
Quarterly / Interim Statement/Forecast
Eckert & Ziegler: Significant improvement in cost items in the first half
year
02.08.2016 / 07:45
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Berlin, 2 August 2016. In the first half of the year, Eckert & Ziegler
Strahlen- und Medizintechnik AG (ISIN DE 0005659700), a specialist for
isotope-based applications in medicine, science and industry headquartered
in Berlin, posted a EUR 1.1 million rise in sales to EUR 70.1 million
compared to the same period in the prior year (+ 2 %). Currency effects and
acquisitions were irrelevant, the nominal growth was largely based on
organic growth.
The sharpest rise in sales of EUR 2.1 million, or 12 %, to EUR 19.4 million
was posted by the Radiopharma segment. While sales of equipment and
cyclotron products remained more or less unchanged year on year, sales of
pharmaceutical radioisotopes posted double-digit growth. The Isotope
Products segment saw sales rise by EUR 1.4 million, or 4 %, to EUR 40.2
million, while, as expected, sales in the Radiation Therapy segment shrank
by EUR 2.7 million, or 18 %, to EUR 12.0 million following the prior year's
disposal of two divisions.
Group earnings per share fell by EUR 0.53, or 37 %, year on year to EUR
0.89. This corresponds more or less exactly to the expected value, which
provides for earnings of EUR 1.80 per share for the full year. If the
earnings for the first half of the year are only calculated on the basis of
the continuing operations and eliminating the losses for 2016 that arose
from the winding-down of a Californian subsidiary, earnings per share
amounted to EUR 0.98, that is to say EUR 0.10 more. The scheduled decline
in profits was due to the EUR 5.9 million drop in extraordinary income
which stood at a record figure of EUR 9.2 million in the prior year as a
result of, among other things, the sale of an investment (OctreoPharm
Sciences). This was compounded in 2015 by a EUR 1.2 million rise in the
financial result - mainly as a result of exchange rate gains.
If extraordinary income and the financial result are excluded for both
halves of the year, there has been a significant improvement in the results
of operations. While sales remained more or less unchanged, the Group's
gross margin rose by EUR 1.3 million and administrative and selling
expenses fell by EUR 2.2 million. The disposals of loss-bringer operations
and the closure of unprofitable subsidiaries enabled the Group to reduce
its cost base by EUR 3.5 million, or 5 % of sales, within a period of
twelve months.
Compared to 2015, more or less constant sales of EUR 140 million are
expected for 2016. Profit is likely to decline to around EUR 1.80 per share
due to the absence of positive one-off effects.
The complete quarterly financial statements can be viewed under:
http://www.ezag.com/fileadmin/user_upload/ezag/investors-financial-reports/
englisch/euz216e.pdf
About Eckert & Ziegler.
Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700), with
approximately 700 employees, is one the world's largest providers of
isotope technology for radiation therapy and nuclear medicine.
Contributing to saving lives.
Your contact:
Eckert & Ziegler AG, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138, [email protected], www.ezag.com
---------------------------------------------------------------------------
02.08.2016 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Eckert & Ziegler Strahlenund Medizintechnik AG
Robert-Rössle-Str.10
13125 Berlin
Germany
Phone: 49 30 941084-138
Fax: 49 30 941084-112
E-mail: [email protected]
Internet: www.ezag.de
ISIN: DE0005659700
WKN: 565970
Listed: Regulated Market in Frankfurt (Prime Standard), Stuttgart;
Regulated Unofficial Market in Berlin, Dusseldorf,
Hamburg, Munich, Tradegate Exchange
End of News DGAP News Service
---------------------------------------------------------------------------
487719 02.08.2016
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
Eckert & Ziegler Strahlen- und Medizintechnik AG ISIN: DE0005659700 können Sie bei EQS abrufen
Medtech , 565970 , EUZ , XETR:EUZ